Great Point Partners’s Context Therapeutics CNTX Stock Holding History

Great Point Partners’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.86M	Sell	2,238,496 -2,445,215	-52%	-$5.71M	1.35%	27
2025 Q4	$6.89M	Hold	4,683,711	–	–	2.23%	19
2025 Q3	$4.54M	Hold	4,683,711	–	–	1.87%	20
2025 Q2	$3.07M	Hold	4,683,711	–	–	2%	21
2025 Q1	$2.87M	Hold	4,683,711	–	–	1.52%	26
2024 Q4	$4.92M	Sell	4,683,711 -2,251,271	-32%	-$3.9M	2.32%	19
2024 Q3	$13.6M	Sell	6,934,982 -484,373	-7%	-$1.07M	4%	9
2024 Q2	$14.9M	Buy	+7,419,355	New	+$12.8M	2.85%	15

Other funds holding CNTX

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Great Point Partners's CNTX Position: Q1 2026 in Review

Great Point Partners reduced its Context Therapeutics (CNTX) stake by 52% in Q1 2026, selling an estimated $5.71M and leaving 2,238,496 shares worth $5.86M. The position accounts for 1.35% of the portfolio, ranked #27.

Great Point Partners first reported a position in CNTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $14.9M in Q2 2024. 59 funds tracked by Wall St. Rank hold CNTX as of Q1 2026.

Great Point Partners held 2,238,496 shares of Context Therapeutics worth $5.86M as of Q1 2026.
Great Point Partners sold 2,445,215 Context Therapeutics shares in Q1 2026, an estimated $5.71M.
Context Therapeutics made up 1.35% of Great Point Partners's portfolio in Q1 2026, its #27 holding.
Great Point Partners first reported a position in Context Therapeutics in Q2 2024 and has held it in 8 quarters since.
Great Point Partners's Context Therapeutics position peaked at $14.9M in Q2 2024.
59 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2026.

Based on Great Point Partners's 13F filing for Q1 2026, filed 15 May 2026.